AOD-9604 Dosage: What the Human Trials Actually Tested
There is no approved AOD-9604 dose. See the IV and oral doses tested in six human trials, why the largest one failed, side effects and FDA status in 2026.
Separating trial doses, animal studies and online injection protocols.
There is no established AOD-9604 dosage for people. The only controlled human trials gave AOD-9604 intravenously or as an oral tablet or capsule, at single IV doses from 25 to 400 micrograms per kilogram of body weight and oral doses from 0.25 mg to 54 mg. The largest trial found no significant weight loss compared with placebo, and the developer ended work on it as an obesity drug in 2007. FDA's 2024 evaluation identified no human studies of subcutaneous AOD-9604, the injection route commonly promoted in online protocols.
Key takeaways
- No approved or recommended dose: AOD-9604 is not an FDA-approved drug. An FDA advisory committee voted 0 to 12 in December 2024 against adding it to the list of substances pharmacies may use for compounding.
- Human trials used IV and oral doses: Six placebo-controlled trials run by Metabolic Pharmaceuticals tested single IV doses, single oral doses and repeated daily oral dosing in 893 participants.
- The big trial missed: In a 24-week trial of 0.25, 0.5 and 1 mg oral tablets in 502 adults with obesity, weight loss was not significantly different from placebo.
- No human subcutaneous injection studies: FDA identified two human IV safety trials but no human studies of subcutaneous or transdermal AOD-9604, and no human pharmacokinetic data for any route.
- Vial math is not a dose: Knowing that a vial holds 10 mg tells you what the label claims, not what amount is safe or effective.
AOD-9604 Human Trial Dosage Chart (Not a Dosing Guide)
| Study | Route and amount | People | Main finding |
|---|---|---|---|
| METAOD001 | IV, single doses of 25 to 400 mcg/kg | 15 healthy men | Side effects similar to placebo; dose-escalation safety only |
| METAOD002 | IV, single doses of 25, 50 and 100 mcg/kg | 23 men with obesity | No serious adverse events; euphoria and one severe chest tightness rated possibly related |
| METAOD003 | Oral, single doses of 9, 27 and 54 mg | 17 men with obesity | Severe diarrhoea classified as a serious adverse event and considered possibly related; bronchial pneumonia considered unrelated |
| METAOD004 | Oral, 9, 27 or 54 mg daily for 7 days | 36 men with obesity | More headache, diarrhea and flatulence at 54 mg |
| METAOD005 | Oral, 1, 5, 10, 20 or 30 mg daily for 12 weeks | 300 adults with obesity | Small weight differences versus placebo; FDA called their meaning unclear |
| METAOD006 (OPTIONS) | Oral, 0.25, 0.5 or 1 mg daily for 24 weeks | 502 adults with obesity | No significant weight loss versus placebo; obesity program ended |
Sources: Stier et al., Journal of Endocrinology and Metabolism, 2013 and FDA's AOD-9604 review for the December 2024 advisory committee. These are historical research doses, not a dosing chart for use.
What is AOD-9604?
AOD-9604 is a 16-amino-acid fragment of human growth hormone (amino acids 177 to 191, with an extra tyrosine added). The name stands for "anti-obesity drug 9604." It was developed in Australia in the late 1990s to copy growth hormone's fat-burning (lipolytic) effect without its other effects. In obese mice, AOD-9604 increased fat oxidation and reduced weight gain without binding the growth hormone receptor or raising blood sugar (Heffernan et al., International Journal of Obesity, 2001).
Is there a recommended AOD-9604 dose?
No. A recommended dose comes from human studies that show which amount works and which amounts cause harm, followed by regulatory review. AOD-9604 never completed that process. FDA's 2024 review concluded there is "a lack of evidence to support the effectiveness of AOD-9604 for the treatment of obesity for any route of administration" and found no human pharmacokinetic or bioavailability data for any route (FDA AOD-9604 review).
The trial doses in the table above are what researchers tested, not amounts shown to be effective. Any specific microgram figure presented online as "the" AOD-9604 dose is a convention from sellers and user communities, not a tested recommendation.
What did the human trials of AOD-9604 find?
Metabolic Pharmaceuticals ran six randomized, double-blind, placebo-controlled trials between 2001 and 2006. Two trials gave single IV doses. Four gave oral doses, from single doses up to daily tablets for 24 weeks (Stier et al., 2013). Across these studies, 893 adults participated. The published 2013 synthesis primarily evaluated safety and tolerability, and its authors included individuals affiliated with the drug developer. The findings therefore require interpretation alongside FDA's independent regulatory assessment.
In the earlier 12-week trial, the authors reported slightly faster weight loss on AOD-9604 than on placebo, for example 0.22 kg per week on 1 mg versus 0.07 kg per week on placebo. FDA noted that these differences were small, of unclear meaning, and published only as a short abstract.
The decisive test was the 24-week OPTIONS trial. Adults with obesity took 0.25, 0.5 or 1 mg tablets daily alongside a supervised diet and exercise program. Weight loss compared with placebo was too low to reach statistical significance at 12 or 24 weeks. On February 21, 2007, the company announced that the results "do not support the commercial viability of the drug as a treatment for obesity" and ended its development for that use.
Where do the AOD-9604 injection doses online come from?
They come from sellers, clinics and user communities, not from human trials. FDA found that compounders had prepared injectable and oral AOD-9604 products marketed by medical spas and wellness clinics. The 2024 FDA evaluation described proposed compounded products containing AOD-9604 at 1,200 mcg/mL for subcutaneous injection, 600 mcg per oral capsule and 600 mcg/g in a topical cream. These were proposed product strengths, not clinically validated dosing recommendations. FDA found no human studies supporting the nominated subcutaneous or transdermal routes.
A 2026 review of growth-hormone-axis peptides, including AOD-9604, compared online self-administration protocols with published evidence and described the uncertainty around product composition, dose and stacking in unregulated supply chains (Dominikowski et al., Frontiers in Endocrinology, 2026).
What AOD-9604 doses were used in animal studies?
- Oral in rats: 500 mcg/kg by mouth daily for 19 days cut weight gain by more than half in obese Zucker rats (Ng et al., Hormone Research, 2000).
- Infusion in mice: Obese mice received AOD-9604 for 14 days through implanted mini-pumps, which reduced weight gain and increased fat oxidation (Heffernan et al., 2001).
- Knee injections in rabbits: 0.25 mg injected into the knee joint weekly improved cartilage scores in a rabbit osteoarthritis model (Kwon et al., Annals of Clinical and Laboratory Science, 2015).
Animal doses do not convert into a human dose. The species, routes and goals differ, and the human oral trials that followed these studies did not produce meaningful weight loss.
Oral vs injectable vs nasal AOD-9604
| Route | Human evidence |
|---|---|
| Oral tablet or capsule | Four trials, up to 24 weeks; no significant weight loss in the largest trial |
| Intravenous | Two single-dose safety trials |
| Subcutaneous injection | No human studies identified by FDA |
| Transdermal or topical cream | No human studies identified by FDA |
| Nasal spray | No human studies identified in our review |
FDA found no human pharmacokinetic data for any route and no human bioavailability data establishing absorption after oral, subcutaneous or other non-IV administration. In pigs, an IV dose had a half-life of about 3 minutes, and oral absorption was unclear even in animals. This animal finding cannot establish AOD-9604's elimination half-life or detection window in humans.
What are the side effects of AOD-9604?
In the six trials, the authors reported side effects similar to placebo, no change in IGF-1 or glucose tolerance, and no antibodies against AOD-9604 in the patients tested. The most common side effects were headache with IV dosing, and headache, diarrhea and flatulence with oral dosing. One participant receiving a 54 mg oral dose experienced severe diarrhoea classified as a serious adverse event and considered possibly related to AOD-9604. Another participant developed bronchial pneumonia, which investigators considered unrelated to treatment. Euphoria (five reports on AOD-9604, none on placebo) and one severe episode of chest tightness were rated possibly related to IV AOD-9604.
FDA read the same data more cautiously. The trial summaries lacked detail and the IV studies were small and short. In the 12-week trial, five participants receiving AOD-9604 reported serious adverse events: basal cell carcinoma, squamous cell carcinoma, breast cancer, malignant melanoma and a moderate lipoma. Investigators considered the events unrelated to treatment, but FDA found the available information insufficient to resolve the safety concerns. Its animal review found possible bone effects in rats, possible liver signals in monkeys and equivocal genotoxicity results. FDA concluded there is insufficient information on long-term safety, and that injected peptides carry a risk of immune reactions from impurities or clumping.
Seek emergency care right away for signs of a severe allergic reaction (anaphylaxis), such as trouble breathing, swelling of the face, lips or throat, widespread hives, or fainting (MedlinePlus: anaphylaxis). Chest pain or tightness also needs urgent medical attention. Problems with a compounded product can be reported to FDA MedWatch.
Is AOD-9604 FDA approved or legal to compound?
AOD-9604 is not FDA-approved for any human use. At the December 4, 2024 Pharmacy Compounding Advisory Committee meeting, members voted 0 in favour and 12 against including AOD-9604 free base and acetate on the 503A Bulks List (FDA committee minutes). This was an advisory recommendation, not a drug-approval decision or a blanket prohibition on possession. FDA's safety-risk page, current as of April 22, 2026, lists AOD-9604 under withdrawn nominations and identifies unresolved safety and product-quality concerns (FDA bulk drug substances page). AOD-9604 was not included among the six peptides covered by HHS's October 2026 interim enforcement-discretion policy for 503A compounding (HHS peptide enforcement-discretion policy). That policy does not provide AOD-9604 with an alternative compounding pathway. For the wider picture, see our FDA-approved peptides list.
AOD-9604 is also on the World Anti-Doping Agency's prohibited list, and anti-doping labs test for it in urine (Thomas et al., Journal of Separation Science, 2015).
AOD-9604 vs tesamorelin
The two are often compared for fat loss but have very different evidence. Tesamorelin is a growth-hormone-releasing hormone analog FDA-approved in formulations marketed as Egrifta SV and Egrifta WR to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, with a labeled dose. AOD-9604 has no approval and no labeled dose. See our tesamorelin FDA approval status guide.
How to read an AOD-9604 vial label
Research suppliers list AOD-9604 in vials labelled by total peptide content, including 10 mg vials. This is a claimed product quantity, not a clinically validated dose or proof of the vial's identity, purity or potency. FDA also noted that AOD-9604 lacks public tests for impurities, aggregates and endotoxin.
For general concentration math, see our peptide calculator. Those calculations describe what a vial contains; they are not dosing instructions and do not make any route safe.
Frequently asked questions
How much AOD-9604 should I take?
There is no established safe and effective AOD-9604 dose for human use. Researchers tested oral amounts from 0.25 mg to 54 mg and single intravenous doses measured by body weight, but the studies did not establish a clinically recommended regimen. The largest obesity trial found no significant weight-loss benefit. AOD-9604 is not an FDA-approved treatment.
Does AOD-9604 work for weight loss?
Not in the trial designed to prove it. The 24-week OPTIONS trial in 502 adults found no significant difference from placebo, and the developer ended the obesity program in 2007.
Is there an AOD-9604 dosage chart?
Only the historical trial doses summarized above. Charts that list daily microgram amounts for injection are not based on human trials.
Does AOD-9604 raise IGF-1?
The trial authors reported no significant change in IGF-1 levels at any dose tested, by IV or by mouth.
About this article: PeptideStack is an affiliate-supported research publisher. The Peptide Partners card on this page is a paid referral offer and is not medical guidance. This article summarises published AOD-9604 research and FDA assessments; it does not recommend purchasing or using AOD-9604. The doses described are historical research exposures, not instructions for human use. For treatment decisions, consult a licensed healthcare professional.
You Might Also Like

Tesamorelin FDA Approval Status 2026
Tesamorelin (Egrifta) FDA approval dates, Phase 1 and Phase 3 trial dates, FDA label indications, latest research 2025-2026, and tesamorelin availability 2026.

FDA Approved Peptides List 2026: Drugs & Pipeline
Current list of clinically approved peptide therapeutics for human use. Popular therapeutic peptides, indications, and new peptides on the market 2026.

List of Peptides and What They Do: Complete Guide 2026
Complete peptide drugs list with uses and examples. All popular peptides, injectable peptides, and anti-inflammatory peptides organized by function.

